(Press-News.org) Like the astronomical explosion that kickstarted the universe, bowel cancer has a “Big Bang” moment which determines how it will grow, according to new research from Cancer Research UK and Wellcome Trust-funded scientists.
Researchers at The Institute of Cancer Research, London, Fondazione Human Technopole in Milan and Chalmers University of Technology in Sweden have found that the “Big Bang” moment for bowel cancer is created by cancer cells successfully hiding themselves from the immune system – a process called immune escape.
During this process, bowel cancer cells disrupt genes which allow the cancer to be detected by the immune system. After the point of immune escape, the scientists observed that very limited changes occurred in how the cancer presented itself to the immune system.
This research provides a potential way that doctors could identify people with bowel cancer who are more likely to respond to immunotherapy, including vaccines for bowel cancer, which are designed to help the immune system recognise and destroy cancer cells.
Professor of Genomics and Evolution and Director of the Centre for Evolution and Cancer at The Institute of Cancer Research, London, Professor Trevor Graham, said:
“Some bowel cancers are ‘born to be bad.’ How they interact with the immune system is set early on.
“Immunotherapy and bowel cancer vaccines hold enormous promise for treating the disease. Our research suggests that a bowel cancer’s relationship with the immune system doesn’t change very much as it grows. If we can target that relationship early on, treatment should have a stronger chance of success.
“As bowel cancer treatment becomes increasingly personalised, understanding how tumours evolve and change matters even more than it did before. Like the explosion which set the course of the universe, bowel cancer’s Big Bang gives us the biggest clues of what its future holds and how we might change that future.”
Bowel cancer is the fourth most common cancer in the UK with around 44,100 new cases in the UK every year, roughly 120 every day. Around 15% of bowel cancers are known to respond well to immunotherapy, with the remainder less likely to respond to this type of treatment.
Several therapeutic bowel cancer vaccines are currently in clinical trials. Designed to train the immune system to prevent bowel cancer from coming back after initial treatment, they recognise and destroy newly emerging bowel cancer cells.
Study lead author Eszter Lakatos, a mathematical biologist at Chalmers University of Technology and the University of Gothenburg, Sweden, said:
”Our research group has investigated and found answers to how cancer cells render themselves invisible to the immune system. Our hope is that these insights will eventually lead to more targeted, effective and early treatments, in addition to surgery.”
In the study, the scientists analysed the organisation of immune and cancer cells in bowel cancers from 29 people. They generated full DNA and RNA sequences and looked at how closely the DNA was wound around proteins in the chromosomes (known as epigenetics).
The scientists found that cancer cells can escape the immune system through epigenetic changes which alter how DNA is “read” to make RNA, the instructions used to make proteins.
In cancer, those alterations affect how many neoantigens - “red flag” proteins that attract immune cells – appear on the surface of the cancer cell. Fewer neoantigens make it harder for the immune system to recognise and destroy the cancer.
Scientists believe that combining immunotherapy with epigenome-modifying drugs could make immunotherapy work better for bowel cancer patients, by making the cancer make more neoantigens which the immune system can target. Further studies are needed to test this idea, before patient clinical trials could start.
Director of Research at Cancer Research UK, Dr Catherine Elliott, said:
“To beat bowel cancer for everyone, we need to understand what happens at the very earliest stages of the disease. No matter how different bowel cancer tumours can look, one defining moment at the start makes a big difference to how the cancer grows.
“Bowel cancer has an insidious ability to resist treatment. Immunotherapy is starting to work well for patients, but it doesn’t work for everyone. This research helps us understand why, as well as giving us new insights to make immunotherapy work better for bowel cancer.”
Research Lead for Discovery Research at the Wellcome Trust, Tom Collins, said:
"Through tracing the earliest stages of bowel cancer, the research team has shed valuable new light on a mechanism that could lead to more targeted, effective and early treatments.
"This is a powerful example of discovery science. Research at this molecular level has provided a deeper understanding of how bowel cancer develops, which could lead to the improved health outcomes for patients in the long-term.”
The paper, titled “Epigenetically driven and early immune evasion in colorectal cancer evolution”, was published today (5 November) in Nature Genetics*.
ENDS
For media enquiries, contact Graeme Sneddon in the Cancer Research UK press office on 07827936507 or, out of hours, on 020 3469 8301.
Notes to Editor
* The paper will be available from https://www.nature.com/articles/s41588-025-02349-1 when the embargo lifts.
About Cancer Research UK:
Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research, influence and information.
Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 50 years.
Cancer Research UK supports research into the prevention and treatment of cancer through the work of over 4,000 scientists, doctors and nurses.
Together with its partners and supporters, Cancer Research UK is working towards a world where people can live longer, better lives, free from the fear of cancer.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook
END
A new study led by the University of Michigan shows that changes in climate are also changing the size of fishes in Michigan's inland lakes. Using data that covered 75 years and nearly 1,500 lakes, researchers have shown that, for several species, old and young fish in 2020 were significantly smaller than their typical size in 1945.
"Climate change is altering the size of different organisms around the world, including fishes in lakes here in Michigan," said Peter Flood, a postdoctoral research fellow at the U-M School for Environment and Sustainability, or SEAS. "And most of those changes we're seeing in Michigan fishes are declines in size through time."
Flood ...
Elevated carbon dioxide levels generated as a result of climate change could significantly increase the temperatures found within the canopies of the world’s woodlands and forests, new research has suggested.
A study by researchers from the UK, Ghana and the USA used thermal imaging technology and other sensors to measure the leaf temperatures found at CO2 levels forecast to occur in 2050.
It found that temperatures within the forest canopies rose by around 1.3°C as a direct consequence of increases in CO2 – from an average of 21.5°C under current conditions to 22.8°C at the predicted 2050 ...
A commonly prescribed antibiotic could help reduce the risk of some young people developing schizophrenia, new research suggests.
Experts found that patients of adolescent mental health services who were treated with the antibiotic doxycycline were significantly less likely to go on to develop schizophrenia in adulthood compared with patients treated with other antibiotics.
Experts say the findings highlight the potential to repurpose an existing, widely used medication as a preventive intervention ...
Delta.g, the UK quantum technology company pioneering quantum gravity sensing for subsurface intelligence, today announced the appointment of Ewen Stevenson as Chair of its Board of Directors, effective immediately.
Ewen Stevenson is a veteran banker with over 20 years of senior management experience and a record in strategic transformation, value creation, innovation, and leadership. He is currently Chair of Serendipity Capital who led Delta.g’s recently closed seed funding round. Prior to Serendipity Capital, he served as Group Chief Financial Officer of HSBC Holdings, following four years as Group Chief Financial Officer of The Royal Bank of Scotland. Prior ...
Because policies to address pollution are costly to implement and impose social burdens, it is important to understand the full benefits of pollution-reducing programs. An article in Health Economics provides compelling evidence that one such program offered considerable benefits for infant health, especially in vulnerable populations.
Based on an analysis of more than a decade of US birth records, the research shows that the Nitrogen Oxide Budget Trading Program—a cap-and-trade initiative to reduce ozone pollution—significantly improved infant health outcomes, particularly among Black, low-income, and single mothers.
The program ...
Cyberwarfare between nation states has become increasingly common in recent years. To address several important questions that this phenomenon raises, scientists developed a game theoretical model of cyberwarfare between nations.
Their research, which is published in Economic Inquiry, focuses on factors that determine the severity and outcomes of cyber conflicts. With a two-country model—where nations invest in offensive or defensive cyber capabilities across networked systems—the investigators considered different scenarios where the Attacker is the ...
A growing body of evidence implicates cellular senescence—when cells age and permanently stop dividing—as an important contributor to metabolic dysfunction that can lead to obesity, type 2 diabetes, and metabolic syndrome. A review in the Journal of Internal Medicine explores the research connecting senescent cells to metabolic diseases and highlights the potential of “senotherapeutics” in treatment strategies.
The authors note that senescent cells accumulate in metabolic tissues where they secrete factors that disrupt tissue ...
Nitrogen metabolism of gut bacteria can provide health benefits. Specifically, gut microbes metabolize dietary nitrates and nitrites and prevent the formation of cancer-causing compounds called nitrosamines. New research published in The FEBS Journal sheds light on these processes and pinpoints which types of bacteria are most important.
Investigators found that Escherichia coli—and to a lesser extent, species of the genera Lactobacillus, Bacteroides and Phocaeicola—can efficiently metabolize different forms of nitrogen, thus ...
Lithium-metal batteries are among the most promising technologies for energy storage. They offer significantly more energy in less space — and at a lower weight. However, one phenomenon slows down their development: tiny, needle-like metal structures called dendrites, made of lithium. They can grow uncontrollably inside the battery and cause devastating short circuits. Until now, solid electrolytes, including polymer-based electrolytes, have been considered a way to suppress this growth.
“Electrolytes are responsible for transporting lithium ions back and forth between the two electrodes inside a battery — making ...
An Osaka Metropolitan University team has used stem cells extracted from adipose, the body’s fatty tissue, to treat spine fractures in rats similar to those caused by osteoporosis in humans. These cells offer the advantages of being easy to collect, even from elderly individuals, and causing little stress to the body, suggesting a non-invasive way of treating bone diseases.
Osteoporosis is a disease that causes bones to become brittle and prone to fractures. Due to the aging of the population, the number of patients in Japan is estimated to ...
